Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
HOME > BUSINESS
BUSINESS
- Eisai to Push Efficacy of Careram in Combination with MTX, Low Drug Costs
September 19, 2012
- MTPC, Daiichi Sankyo Conduct Largest Ever Copromotion for Tenelia, Aiming for Top Position in Diabetes Market with SGLT-2 Inhibitor
September 19, 2012
- Teva Appoints Itzhak Krinsky as Chairman for Japan, South Korea
September 18, 2012
- Chugai Provides All-Case PMS Data via iPad, Beginning with Avastin
September 18, 2012
- Kaketsuken Starts PIII Trial for Cell-Culture-Based New-Type Influenza Vaccine
September 18, 2012
- Astellas Launches Enzalutamide in the US
September 18, 2012
- 100,000 Registrations Expected by End of Year on Japan Vaccine’s Mobile Phone Vaccination Website
September 18, 2012
- Kyowa Kirin to Return Rights for Busulfex in Japan and Asia to Otsuka
September 18, 2012
- Detailing with iPad Rapidly Increases, Up 21.6 Points to 48.8%: Doctor Survey
September 14, 2012
- JT Sees Silver Lining in Pharmaceutical Biz 25 Yrs after Market Entry; 1st Approval Obtained for Proprietary Drug
September 14, 2012
- Eisai Ties up with US NPO to Support Vaccine Development for Tropical Diseases
September 14, 2012
- Eisai Launches Next Mainstay Product in Europe; Antiepileptic Perampanel
September 14, 2012
- MTPC Files for Additional Indication of Chronic Atrial Fibrillation for Maintate
September 14, 2012
- Bayer Yakuhin Granted Priority Review for NDA for Regorafenib
September 13, 2012
- Takeda Completes New Russian Factory, Full-Scale Operation Scheduled in 2014
September 13, 2012
- FDA Accepts Resubmission of NDA for Once-Monthly Aripiprazole Injection: Otsuka
September 13, 2012
- Pfizer Japan Files Add’l Indication of MS for Solu-Medrol Based on Data from Public Domain
September 13, 2012
- Eli Lilly Files Public Knowledge-Based Application for Gemzar for Malignant Lymphoma
September 12, 2012
- Wholesalers Unlikely to See Significant Progress in Price Negotiations By End of September
September 12, 2012
- Taisho Toyama, Eisai Launch Anti-Rheumatic Drug Kolbet/Careram on Sept. 12
September 12, 2012
ページ
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
The advance of cell therapy is one of the most exciting innovations in medical treatment in recent years. These drugs offer potential curative treatments for severe or previously fatal diseases. In this article, I will explain features and challenges in…
The Liberal Democratic Party (LDP) will wrap up its discussions on the FY2023 tax reform plan within a few days. Some provisions of the R&D tax credit system, which allow drug makers to deduct a portion of R&D expenses from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…